info@synapsdx.com
Facebook-f
Linkedin-in
Instagram
Menu
FOR PATIENTS
FOR PROVIDERS
ABOUT US
CONTACT US
NEWS
Part I: Accurately Diagnosing Alzheimer’s Disease: Shortcomings of Blood Biomarkers and Need for Definitive, Non-invasive Diagnostic Testing
Author of publication
Dr. Daniel Alkon, chief scientific advisor, SDx
Download
Synaps Dx
Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients
Prev post
Part II: Accurately Diagnosing Alzheimer’s Disease: Shortcomings of Blood Biomarkers and Need for Definitive, Non-invasive Diagnostic Testing
Next post
Search for:
Recent Posts
New Recommendation from FDA Advisory Committee: Using Rexulti to Treat Agitation Associated with Alzheimer’s Disease
Six Ways to Support Cognitive Health for Older Adults
The Cost Burdens of Diagnosing and Treating Alzheimer’s Disease: Alarming Issues for Patients, Providers and Payers Nationwide
Clinician Alert: Identify the Right Patients at the Right Time for Disease Modifying Therapies to Address Alzheimer’s Disease
Seven Ways to Care for Your Brain
Recent Comments
Archives
May 2023
April 2023
March 2023
February 2023
January 2023
November 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
October 2019
September 2019
December 2018
November 2018
Categories
Uncategorized
Meta
Log in
Entries feed
Comments feed
WordPress.org
Input your search keywords and press Enter.
Recent Comments